Chartis’ Post

Did you miss AtlanticLIVE's #PeoplevCancer "Prevention is Power: Advancements in Early Detection" discussion? It features insights from NMQF President and CEO Dr. Gary Puckrein on gaps in cancer care, NMQF's Cancer Stage Shifting Initiative (which is aligned with The White House's #CancerMoonshot 2.0), and how we can work collaboratively to advance equitable cancer care. ➡️ https://lnkd.in/esRG-kji

Breaking down barriers in cancer care and diagnosis, one innovation at a time. 💡👏 In Europe, Germany remains in the lead, but the UK, France, Switzerland and the Netherlands are making significant progress in the battle against cancer. For more insights, dive into our latest #EPOStudy: epo.org/trends-cancer #FightCancer #CancerAwareness #InnovationInHealthcare #WorldCancerDay

Our Chief Scientific Officer and Co-founder, Brian Fiske, Ph.D., recently sat down with ApexOnco’s Jacob Plieth to discuss our unique approach to #ADCs for #cancer patients. With enhanced internalization and targeted release mechanisms, our ADCs are designed to benefit a broader patient population. Discover how we are pushing the boundaries of cancer treatment by reading the full article here: https://bit.ly/3xPerkf 

FORCE's XRAY reviews are short, plain language summaries of current issues about hereditary cancer. These include audience relevance, national guidelines, questions enrolling clinical trials and resources. Read more at: https://ow.ly/u6Ay50QL0FU #FacingOurRisk #hereditarycancer

FORCE's XRAY reviews are short, plain language summaries of current issues about hereditary cancer. These include audience relevance, national guidelines, questions enrolling clinical trials and resources. Read more at: https://ow.ly/u6Ay50QL0FU #FacingOurRisk #HereditaryCancer

Developing innovative medicines is not enough if the treatments don’t reach the patients who need them. Read more from our Gerwin Winter, SVP, Head of Europe, and Eric Low in this in this Oncology Central article about how an access-driven approach that prioritizes patient needs is crucial. https://lnkd.in/eTrC9aik

FORCE's XRAY reviews are short, plain language summaries of current issues about hereditary cancer. These include audience relevance, national guidelines, questions enrolling clinical trials and resources. Read more at: https://ow.ly/u6Ay50QL0FU #FacingOurRisk #HereditaryCancer

Event (10/18): 'Fall Cancer Conference: Misinformation, Myths & Misbeliefs,' presented by the UW Carbone Cancer Center. #Cancer misinformation has become an increasingly prevalent problem, potentially endangering #publichealth and understanding. Learn the latest from experts in the field. The conference, taking place at the Monona Terrace Community and Convention Center, is designed for #healthcare professionals, as well as patients and loved ones. Learn more and register: https://lnkd.in/gFGWNDUr #Wisconsin #clinicalresearch #clinicaltrials #healthequity

We participate in clinical trials because we want to improve the health and quality of life for our patients in treating, managing, and preventing cancer. As a CCWW patient, you have access to clinical trials for any type of cancer at any stage. Recognized by the National Cancer Institute (NCI) for exceptional achievement in enrolling patients in clinical trials, Dr. Mescher will help find if participating in a research study may be right for you. #clinicaltrials #cancerresearch

Our recent survey showed that 36.8% of people found it difficult to live on their usual household income after a lung cancer diagnosis.💔 Find out more in the 8th LuCE report, with data received from over 1,161 participants in Europe! As part of our mission, our LuCE Reports aim to highlight the many challenges faced by the lung cancer community. Read this and all our previous reports at https://lnkd.in/dmuzqgvD #lcam #lcsm #lungcancerawareness #lungcancerfinancialeffect #cancerdiagnosis #lungcancerdiagnosis #lungcancer #lungcancerexpenses #lungcancerawarenessmonth #lungcancerawareness #cancerawareness #lungcancerreport